Prevalence and Survival Outcomes of L1 Cell Adhesion Molecule–Positive in Endometrial Cancer Across Molecular Subtypes: A Systematic Review and Meta-Analysis
JCO Global Oncology · 2026-03 · 12 (3)
DOI: 10.1200/go-25-00519 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JCO Global Oncology, 2026-03. Verfasst von Hiba Siddiqui und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Dr. Ziauddin University Hospital, Karachi, Pakistan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neural Cell Adhesion Molecule L1, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
PURPOSE L1 cell adhesion molecule (L1CAM) has emerged as a potential prognostic biomarker in endometrial cancer. This systematic review and meta-analysis aimed to comprehensively evaluate the prevalence of L1CAM expression across molecular subtypes of endometrial cancer and its prognostic significance for survival outcomes. MATERIALS AND METHODS A systematic literature search of PubMed, Embase, and Cochrane Library was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible studies reporting L1CAM expression in endometrial cancer, stratified by molecular subtypes (polymerase epsilon [POLE], mismatch repair deficiency [MMR-D], no specific molecular profile [NSMP], p53 wild type [p53wt], p53 abnormal [p53abn]), and their association with survival outcomes were included. Pooled prevalence and hazard ratios with 95% CIs were calculated using random-effects models. RESULTS Twenty-one retrospective studies met the inclusion criteria. The overall pooled prevalence of L1CAM positivity was 15%. Stratified by molecular subtype, prevalence was the lowest in POLE-mutated tumors (4.87%), followed by p53abn tumors (52.86%), MMR-D tumors (52.16%), NSMP (30.88%), and p53wt (25.99%). L1CAM positivity was significantly associated with worse disease-specific survival (hazard ratio [HR], 2.49 [95% CI, 1.75 to 3.55]) and progression-free survival (HR, 2.50 [95% CI, 1.56 to 4.01]). Subgroup analyses revealed significant associations in MMR-D tumors (HR, 1.75 [95% CI, 1.06 to 2.89]), NSMP tumors (HR, 5.41 [95% CI, 2.92 to 10.03]), and a borderline effect in p53abn tumors (HR, 1.69 [95% CI, 1.00 to 2.85]). CONCLUSION The highest prevalence of L1CAM was found in p53abn endometrial tumors. L1CAM positivity is associated with poor survival outcomes, particularly in MMR-D and NSMP subgroups. These findings highlight the potential of L1CAM as a prognostic biomarker that could refine risk stratification and guide adjuvant management more accurately in endometrial cancer, warranting validation in prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Dr. Ziauddin University Hospital, Karachi, Pakistan.
- Department of Internal Medicine, Koç University Hospital, Istanbul, Turkey.
- Department of Surgery, University of Alabama, Birmingham, AL.
ORCID-Profile: Hiba Siddiqui, Turkan Aliyeva, Sailesh Kumar
Zitieren
APA
Siddiqui, H., Aliyeva, T., & Kumar, S. (2026). Prevalence and Survival Outcomes of L1 Cell Adhesion Molecule–Positive in Endometrial Cancer Across Molecular Subtypes: A Systematic Review and Meta-Analysis. JCO Global Oncology, 12(3). https://doi.org/10.1200/go-25-00519
Vancouver
Siddiqui H, Aliyeva T, Kumar S. Prevalence and Survival Outcomes of L1 Cell Adhesion Molecule–Positive in Endometrial Cancer Across Molecular Subtypes: A Systematic Review and Meta-Analysis. JCO Global Oncology. 2026;12(3). doi:10.1200/go-25-00519
BibTeX
@article{Siddiqui2026,
author = {Siddiqui, Hiba and Aliyeva, Turkan and Kumar, Sailesh},
title = {Prevalence and Survival Outcomes of L1 Cell Adhesion Molecule–Positive in Endometrial Cancer Across Molecular Subtypes: A Systematic Review and Meta-Analysis},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {3},
doi = {10.1200/go-25-00519}
}
EUVIMED